A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

In 2003, bortezomib (Velcade; Millenium) became the first drug approved by the US FDA for use in patients with relapsed or refractory MM. Bortezomib, given intravenously, inhibits the 26S ...

Background. A 59-year-old woman presented to the emergency department with a left rib fracture and was diagnosed with IgA multiple myeloma. The patient underwent autologous bone-marrow ...

Jerry Cowhig, a father of two children from Bristol, was diagnosed with myeloma aged 68, following a year of excruciating ...

Forty-eight patients with multiple myeloma, most of them ambulatory outpatients ... osteolytic lesions and bone-marrow plasmacytosis). 7 The disease was classified as in partial remission ...

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...

Graham Casey, from Bearsden in East Dunbartonshire, was 63 when he was diagnosed with myeloma - a form of blood cancer - in October 2022. The disease had left him barely able to move or sleep ...

The family of a man employed in the maintenance department of the Pleasant Valley School District stricken with a rare blood and bone cancer will be among several beneficiaries of a fundraiser held ...

Learn the key facts about blood cancer, including symptoms, early detection, and treatment options. Knowledge could save lives.

GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

Initial clinical observations suggest high level of T cells reprogramming and CAR-T expansion at the starting dose without lymphodepletion At 28 ...